Brokerages expect FibroGen Inc (NASDAQ:FGEN) to report $46.10 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for FibroGen’s earnings, with estimates ranging from $37.70 million to $50.90 million. FibroGen posted sales of $27.27 million during the same quarter last year, which suggests a positive year-over-year growth rate of 69.1%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that FibroGen will report full year sales of $207.90 million for the current year, with estimates ranging from $135.40 million to $256.80 million. For the next fiscal year, analysts forecast that the business will report sales of $238.43 million, with estimates ranging from $92.00 million to $345.30 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow FibroGen.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.31. The business had revenue of $43.95 million for the quarter, compared to analyst estimates of $28.70 million. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%.
In related news, SVP Pat Cotroneo sold 1,011 shares of FibroGen stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $57.35, for a total transaction of $57,980.85. Following the sale, the senior vice president now directly owns 220,422 shares of the company’s stock, valued at $12,641,201.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction dated Thursday, October 18th. The stock was sold at an average price of $54.52, for a total value of $1,030,428.00. Following the sale, the chief executive officer now directly owns 2,710,412 shares in the company, valued at $147,771,662.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 236,673 shares of company stock worth $14,005,902. 8.96% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Emerald Advisers Inc. PA acquired a new stake in FibroGen during the second quarter worth about $22,954,000. Hillhouse Capital Management Ltd. grew its position in FibroGen by 3.2% during the second quarter. Hillhouse Capital Management Ltd. now owns 2,686,196 shares of the biopharmaceutical company’s stock worth $168,156,000 after buying an additional 83,850 shares in the last quarter. Rhenman & Partners Asset Management AB grew its position in FibroGen by 4.9% during the third quarter. Rhenman & Partners Asset Management AB now owns 251,190 shares of the biopharmaceutical company’s stock worth $15,260,000 after buying an additional 11,643 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in FibroGen by 20.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 469,708 shares of the biopharmaceutical company’s stock worth $29,404,000 after buying an additional 81,074 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in FibroGen during the third quarter worth about $486,000. 76.08% of the stock is currently owned by institutional investors and hedge funds.
Shares of FibroGen stock traded down $0.54 during trading on Friday, reaching $46.82. The company’s stock had a trading volume of 486,338 shares, compared to its average volume of 583,437. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.95 and a current ratio of 7.95. The firm has a market capitalization of $3.95 billion, a PE ratio of -27.06 and a beta of 1.81. FibroGen has a one year low of $40.74 and a one year high of $68.55.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Recommended Story: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.